

QIBA FDG-PET/CT Tech Ctte
ACRIN 6678 Test/Retest Discussion
30 August 2012 at 9 AM CT (GMT-5)
Draft Call Summary

In attendance:

Paul E. Kinahan, PhD (co-chair)

Andrew Buckler, MS
Janice Campbell, PhD
Paul E. Christian
David A. Clunie, MBBS
Patricia E. Cole, PhD, MD
Robert K. Doot, PhD
Constantine Gatsonis, PhD
Michael Graham, MD, PhD
Howard Higley, PhD

Yuying C. Hwang, PhD
Martin A. Lodge, PhD
Lawrence MacDonald, PhD
Neru Munshi, PhD
Dennis Nelson, PhD
Eric S. Perlman, MD
Barry Siegel, MD
Rathan Subramaniam, MD
Daniel C. Sullivan, MD
John J. Sunderland, PhD
Valerie Treyer, PhD

Timothy G. Turkington, PhD
Wenli Wang, PhD
Scott D. Wollenweber, PhD
John G. Wolodzko, PhD
Jeffrey T. Yap, PhD

RSNA

Julie Lisiecki

ACRIN 6678 Test/Retest Discussion

- Drs. Gatsonis and Siegel joined the call to answer statistical questions and help the group to understand how the ACRIN 6678 test-retest results relate to the QIBA FDG-PET Technical Committee's Profile Claim language
- The ACRIN group is examining SUV_{max} with a 12% coefficient of variation, and a $\pm 33\%$ range of repeatability
 - Aiming for a balance between scientific precision and clinical usefulness
 - Current data is based on 34 participants
- The study is very similar to one completed by Dr. Velasquez.
 - Her paper was recommended as an excellent reference for the group.

Comments regarding the ACRIN 6678 Draft Interim Report

The group reviewed and discussed areas of particular interest or concern including:

- Asymmetry of repeatability coefficients
- Similarity of SUV_{max} and SUV peak test-retest reproducibility
- Coefficient of Variation (COV) used in ACRIN 6678

Follow up items

- Dr. Gatsonis to send cov information to Dr. Kinahan for distribution to the group.
- Technical Committee to adjust claim using Dr. Gatsonis' numbers
- Dr. Kinahan will send the updated version of the claim to Dr. Gatsonis for review
- RSNA Staff to send latest version of the QIBA FDG-PET Profile to Dr. Campbell for review
- RSNA Staff to arrange t-con including Drs. Lodge and Yap to address remaining items that require their expertise

Next steps:

- Approach to addressing the Public Comment phase needs further discussion, along with resolving the ACRIN 6678 test-retest results in relation to the claim.

Next call:

- Post - ACRIN 6678 Discussion of claim and remaining action items, **Friday, August 31st, at 9 am CT.**